The two medicines are generic versions of Roche Holding AG's (SWX: ROG) original drug CellCept, which the EMEA approved in 1996. "Reuters" noted that marketing recommendation by the EMEA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

Teva closed at $44.40 on Nasdaq on Friday, giving a market cap of $34 billion. The share rose 0.3% in after-hours trading, and fell 1% at the opening on the TASE today.